Kyowa Kirin said on June 25 that it has obtained Japanese regulatory approval for an additional pre-filled syringe formulation of its X-linked hypophosphatemia therapy Crysvita (burosumab).The drug was approved as a vial form for the treatment of FGF23-related hypophosphatemic rickets…
To read the full story
BUSINESS
- Pfizer to Drop Avastin, Herceptin Biosimilars in Japan, Halving Portfolio
October 14, 2026
- Asahi Kasei’s Pritelivir Scores US Approval for HSV Infections
October 14, 2026
- Nitto Medic Recalls Heparinoid Lotion over Nitrosamine Impurity
October 14, 2026
- Moderna Rolls Out XFG-Updated Pediatric Spikevax in Japan
October 14, 2026
- Taiho to Take Over Haiyitan Marketing Authorization from Haihe
October 14, 2026
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…





